WISC 2016 Keynote Speakers

The Mucosal Leukotriene E4 Receptor CysLT3R Regulates Secretion and Responds to the Mast Cell

K. Frank Austen (United States) attended Amherst College and Harvard Medical School and served his house staff training years at the Massachusetts General Hospital (MGH). He established an independent laboratory at the MGH in 1962 and moved to the Robert B. Brigham in 1966 to establish a Department of Rheumatology and Immunology which evolved into a department of the Brigham and Women’s Hospital (BWH). After chairing this Department for 25 years, he shifted to the AstraZeneca Professorship of Respiratory and Inflammatory Diseases. Austen has pioneered many aspects of innate immunity/inflammation through an in depth focus on the functions and regulation of arachidonic acid metabolism to the cysteinyl leukotrienes (cysLTs), the pathways for the development and phenotypic diversity of mast cells, and the pattern recognition path for activation of the alternative complement activating pathway which also serves to amplify the classical complement pathway.

Austen was elected to the National Academy of Sciences and to the American Academy of Arts and Sciences in 1974 and as a foreign member of the Royal Society (UK) in 2004. He has served as President of the American Association of Immunologists, the American Academy of Allergy, Asthma and Immunology, and the American Association of Physicians.

Eosinophilic Esophagitis: A Rising Concern

Marc Rothenberg (United States) is the Director of the Division of Allergy and Immunology at Cincinnati Children’s Hospital Medical Center (Cincinnati Children’s), a tenured Professor of Pediatrics at Cincinnati Children’s and the University of Cincinnati College of Medicine (UCCOM), the Founder and Director of the Cincinnati Center for Eosinophilic Disorders (CCED), and the Founder and Director of the NIH--‐sponsored, national Consortium of Eosinophilic Disease Researchers (CEGIR). He graduated summa cum laude with Highest Honors in Chemistry and Biochemistry from Brandeis University. At Harvard Medical School (HMS), he completed the combined MD/PhD program. His PhD under the mentorship of Dr. Frank Austen included seminal studies on eosinophil hematopoiesis, identifying and characterizing the original biology of eosinophilopoeitins, which led to the development of a new class of drugs (humanized anti--‐IL--‐5). After completing a residency in pediatrics at Children’s Hospital in Boston, Dr. Rothenberg did a combined fellowship in Allergy/Immunology and Hematology at Children’s Hospital in Boston. Rothenberg did post--‐doctorate training in the genetics laboratory of Dr. Philip Leder at HMS, where he cloned the eotaxin chemokine, which opened up a new direction in allergy research. He came to the UCCOM and Cincinnati Children’s in 1996 and has helped build a top program in pediatric research; his division is a leader in pediatric allergy and immunology. His research is focused on molecular analysis of allergic inflammation, primarily on the pathogenesis of eosinophilic gastrointestinal disorders (EGIDs). His laboratory takes multi--‐disciplinary approaches including the development of preclinical murine models of allergic disease, genetics, genomics, molecular immunology, cellular biology, and biochemistry.

Dr. Rothenberg’s awards include the 2007 E. Mead Johnson Award from the Society of Pediatric Research, an NIH MERIT Award in 2010 and he is a member of the Hewlett--‐Woodmere Alumni Hall of Fame. He is an elected member of the ASCI, AAP, AAAS and SPR. His publications number over 325. He has served on various review panels for journals and grant agencies including the NIH, Burroughs Trust, the MRC of the UK and the ISF of Israel. He is an Associate Editor of the Journal of Allergy and Clinical Immunology, and Mucosal Immunology, and co--‐Section Head of the Allergy and Hypersensitivity Section of Faculty 1000. He has served a four--‐year term on the Advisory Council of the NIAID. His research has been supported by numerous sources including the NIH, Human Frontier Science Program Organization, the Burroughs Wellcome Fund, the Dana Foundation, the US Department of Defense, US--‐Israel Binational Fund, and PCORI. He has trained a myriad of clinical and research investigators in his own laboratory and also as Program Director and/or Co--‐Principal Investigator of several NIH training grants including the NIH CTSA KL2, NICHD CHRCDA K12, and NIAID T32.

The Ubiquitin System in Health and Disease

Avram Hershko (Israel) was born in 1937 in Hungary and emigrated with his family to Israel in 1950. He gained his MD (1965) and PhD (1969) from the Hebrew University - Hadassah Medical School of Jerusalem. After a post-doctoral fellowship at the University of California of San Francisco (1969-72), he joined the faculty of the Haifa Technion becoming professor in 1980. He is now Distinguished Professor in the Unit of Biochemistry in the B. Rappaport Faculty of Medicine of the Technion. His main research interests concern the mechanisms by which cellular proteins are degraded, a formerly neglected field of study. Hershko and his colleagues showed that cellular proteins are degraded by a highly selective system. This system tags proteins for destruction by linkage of a protein called ubiquitin, which had previously been identified in many tissues, as the name suggests, but whose function was previously unknown. Subsequent work in Hershko’s and many other laboratories has shown that the ubiquitin system has a vital role in controlling a wide range of cellular processes, such as the regulation of cell division, signal transduction and DNA repair. Abnormalities in the ubiquitin system result in diseases such as certain types of cancer. The full range of functions of the ubiquitin system in health and disease has still to be elucidated.

Hershko was awarded the Nobel Prize in Chemistry (2004) jointly with his former PhD student Aaron Ciechanover and his colleague Irwin Rose. His many other honors include the Israel Prize for Biochemistry (1994), the Gairdner Award (1999), The Alfred P. Sloan Prize of the General Motors Cancer Research Foundation (2000), the Lasker Prize for Basic Medical Research (2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001). Hershko is a member of the Israel Academy of Sciences (2000) and a Foreign Associate of the US Academy of Sciences (2003).

Perturbing Early Life Microbiota Development and Its Immunologic Consequences

Martin J. Blaser (United States) is the Muriel and George Singer Professor of Medicine, Professor of Microbiology, and Director of the Human Microbiome Program at the NYU School of Medicine. He served as Chair of the Department of Medicine at NYU from 2000-2012. A physician and microbiologist, Dr. Blaser is interested in understanding the relationships we have with our persistently colonizing bacteria. His work over 30 years focused on particular organisms, including Campylobacter species and Helicobacter pylori, which also are model systems for understanding the interactions of residential bacteria with their human hosts. Over the last 15 years, he has been actively studying the relationship of the human microbiome with health and with such important diseases as asthma, obesity, diabetes, and allergies.

Over the course of his career, Dr. Blaser has served as the advisor for a large number of students, post-doctoral fellows, and junior faculty. He served as President of the Infectious Diseases Society of America, Chair of the Board of Scientific Counselors of the National Cancer Institute, Chair of the Advisory Board for Clinical Research of the National Institutes of Health, and on the Scientific Advisory Board of the Doris Duke Charitable Foundation. He was elected to the National Academy of Medicine and the American Academy for Arts and Sciences. He holds 25 U.S. patents relating to his research, and has authored over 540 original articles. Recently, he wrote “Missing Microbes”, a book targeted to general